Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764514 | 0.84 | MLYCD (0.42) | RAB9ANPC1 | |
| SCHEMBL20764516 | 0.84 | MLYCD (0.42) | RAB9ANPC1 | |
| SCHEMBL22076705 | 0.84 | LTA4H (0.45) | CYP2C9SLC1A3SLC1A2SLC1A1TAAR1 | |
| SCHEMBL28373495 | 0.81 | CYP2C9 (0.35) | CYP2C9SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL30625935 | 0.78 | SMN1; SMN2 (0.48) | CYP2C9SMN1; SMN2HTTRAB9ANPC1 | |
| SCHEMBL28776911 | 0.74 | MAPT (0.35) | PSMB8PSMB5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL22070158 | 0.73 | TAAR1 (0.46) | SMN1; SMN2HTTRAB9ASLC1A3SLC1A2 | |
| SCHEMBL22076710 | 0.73 | CYP2C9 (0.32) | CYP2C9 | |
| SCHEMBL31045317 | 0.72 | HDAC8 (0.52) | — | |
| SCHEMBL17870500 | 0.70 | PSMB8 (0.37) | PSMB8SMN1; SMN2HTTPSMB5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| EP-3672937-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
| WO-2019038405-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | CYP2C9 438/4885MAOB 555/4885PSMB8 2909/4885 |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | CTH, CBS, SLC7A11 | CYP2C9 463/4885MAOB 847/4885PSMB8 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.